At the 13th Uppsala University Symposium on Pharmaceutical Profiling in Drug Discovery and Development, Professor Thomas Helleday presents new data on OXC-101, Oxcia’s mitotic MTH1 inhibitor, in psoriasis – a new indication for the project. OXC-101 is developed for cancer treatment, but in this research Oxcia has found interesting data …
